Black Friday Sale: 20% off everything. Ends Tuesday 1 December, 11:59 pm AEDT.
For laboratory and research use only. Not for human consumption.  Sold exclusively to qualified researchers and licensed laboratories.

CATALOGUE  /  RETATRUTIDE

RETATRUTIDE 10MG / 20MG

Retatrutide, lyophilised powder in a sealed vial

Retatrutide

Research peptide · Lyophilised powder in a sealed vial · for laboratory and research use only

Retatrutide 10mg Quantity per vial: 10mg
$129.99$103.99
Retatrutide 20mg Quantity per vial: 20mg
$219.99$175.99
Secure card payments
Not a drug, food or cosmetic. For laboratory and research use only. Not for human consumption. This product has not been evaluated or approved by the US Food and Drug Administration (FDA) or the Australian Therapeutic Goods Administration (TGA), and it is not intended to diagnose, treat, cure or prevent any disease. Sold exclusively to qualified researchers and licensed laboratories.

Reagent specifications

CAS number2381089-83-2 (PubChem depositor records)
Molecular weight4731 g/mol (PubChem computed reference value)
StorageSealed, dry and dark at −20 °C or colder; −50 to −80 °C for long-term storage
Certificate of analysisAvailable on request · Request a COA

CAS number and molecular weight are reference values for the compound identity, from PubChem.

Compound identity

Compound classSynthetic fatty-acid-modified peptide; GIP, GLP-1 and glucagon receptor agonist
Development codeLY3437943
StructureContains non-coded residues (α-aminoisobutyric acid at position 2, α-methyl-L-leucine at position 13) and a fatty diacid linked to lysine 17; cannot be written fully in one-letter code
Molecular formulaC221H342N46O68 (PubChem)
PubChem CID171390338
DeveloperEli Lilly and Company (investigational; not approved)
Supplied asLyophilised powder, sealed vial
Quantity per vial10 mg or 20 mg
Intended useLaboratory and research use only

About Retatrutide

Retatrutide (development code LY3437943) is a synthetic, fatty-acid-modified peptide that acts as an agonist at three receptors, the GIP, GLP-1 and glucagon receptors, hence the term "triple agonist". Its sequence contains non-coded residues (α-aminoisobutyric acid at position 2 and α-methyl-L-leucine at position 13) and a fatty diacid linked to lysine 17, so it cannot be written fully in one-letter code.1 Cryo-electron microscopy structures published in 2024 show the peptide bound to each of the three receptors as a single continuous helix.2 It is an investigational compound developed by Eli Lilly and Company and is not approved as a medicine in any country.

Titan Peptides supplies research-grade retatrutide as a lyophilised powder in sealed 10 mg and 20 mg vials, for laboratory and research use only. It is not the developer's material. It is a research chemical: not a drug, food or cosmetic, and not for human consumption.

Status in Australia

Retatrutide is not named in the Poisons Standard June 2026 (F2026L00633).3 The TGA's 13 April 2026 safety advisory nonetheless names retatrutide as an example of an unapproved peptide product, one that has not been evaluated by the TGA for safety, quality or effectiveness, and states that a "research use only" disclaimer does not make supply lawful.4

Retatrutide is not an approved therapeutic good in Australia or elsewhere. See research peptides and Australian law.

Laboratory handling & storage

Store sealed vials dry, dark and frozen at −20 °C or colder, moving to −50 to −80 °C for long-term storage, and let each vial reach room temperature in a desiccator before opening. Keep solutions short-lived: divide a reconstituted stock into single-use aliquots, freeze them and avoid freeze–thaw cycles. Container choice matters at low concentrations, too: a study of endocrine peptides, GLP-1 among them, found that recovery differed between tube surfaces, so check recovery rather than assume it. See how to store peptides and reconstituting peptides with bacteriostatic or sterile water for the reasoning behind each step.

Retatrutide quick answers

What quantities is retatrutide available in?

Research-grade retatrutide is supplied as a lyophilised powder in sealed vials of either 10 mg or 20 mg, for laboratory and research use only. Both contain the same compound; the figure is the quantity per vial. Neither is the developer's material, and neither is for human consumption.

What is retatrutide's CAS number and molecular formula?

PubChem depositor records give retatrutide the CAS number 2381089-83-2, and PubChem (CID 171390338) lists the formula C221H342N46O68 with a computed molar mass of 4731 g/mol. Its sequence cannot be written fully in one-letter code because it contains α-aminoisobutyric acid, α-methyl-L-leucine and a fatty diacid attached at lysine 17.

Is retatrutide legal in Australia?

Retatrutide is not approved by the TGA or any other regulator. It is not named in the June 2026 Poisons Standard, but the TGA lists it as an example of an unapproved peptide product and says a research-use-only label does not make supply lawful.

What does LY3437943 refer to?

LY3437943 is Eli Lilly's development code for retatrutide. Searching chemical and structural databases under both names captures the full literature on the compound.

From the research library

Compound Profiles

Retatrutide: Compound Profile of the Triple Agonist

A chemical profile of retatrutide (LY3437943): what "triple agonist" means at the receptor level, its non-coded residues and fatty diacid, its identifiers, laboratory handling and regulatory status.

21 September 2026 · 3 min read

References

  1. PubChem. Retatrutide, CID 171390338. National Center for Biotechnology Information. Source
  2. Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discov. 2024;10(1):77. PubMed 39019866
  3. Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026 (Standard for the Uniform Scheduling of Medicines and Poisons No. 48), F2026L00633. Commenced 1 June 2026. Federal Register of Legislation. Source
  4. Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products (safety advisory). Published 13 April 2026. Source
Research use only. Not a drug, food or cosmetic. Retatrutide is supplied strictly for laboratory and in-vitro research and is not for human consumption. It is not an approved therapeutic good in Australia, has not been evaluated or approved by the FDA or the TGA, and is not intended to diagnose, treat, cure or prevent any disease. Titan Peptides sells exclusively to qualified researchers and licensed laboratories.